Immunomodulatory potential of secretome from cartilage cells and mesenchymal stromal cells in an arthritic context: From predictive fiction toward reality

Alessandra Colombini1*, Francesca Libonati1, Silvia Lopa2, Enrico Ragni1, Paola De Luca1, Luigi Zagra3, Federico Sinigaglia1, Matteo Moretti2,4,5,6 and Laura de Girolamo1

1Laboratorio di Biotecnologie Applicate all’Ortopedia, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy, 2Cell and Tissue Engineering Laboratory, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy, 3Hip Department, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy, 4Regenerative Medicine Technologies Lab, Laboratories for Translational Research (LRT), Ente Ospedaliero Cantonale, Bellinzona, Switzerland, 5Department of Surgery, Service of Orthopaedics and Traumatology, Ente Ospedaliero Cantonale, Lugano, Switzerland, 6Faculty of Biomedical Sciences, Euler Institute, USI, Lugano, Switzerland

The purpose of the present study is to predict by bioinformatics the activity of the extracellular vesicle (EV)-embedded micro RNA (miRNAs) secreted by cartilage cells (CCs), adipose tissue-derived- (ASCs), and bone marrow-derived stem cells (BMSCs) and verify their immunomodulatory potential supporting our bioinformatics findings to optimize the autologous cell-based therapeutic strategies for osteoarthritis (OA) management. Cells were isolated from surgical waste tissues of three patients who underwent total hip replacement, expanded and the EVs were collected. The expression of EV-embedded miRNA was evaluated with the QuantStudio 12 K Flex OpenArray® platform. Mientournet and ingenuity pathway analysis (IPA) were used for validated target prediction analysis and to identify miRNAs involved in OA and inflammation. Cells shared the expression of 325 miRNAs embedded in EVs and differed for the expression of a small number of them. Mientournet revealed no results for miRNAs selectively expressed by ASCs, whereas miRNA expressed by CCs and BMSCs were putatively involved in the modulation of cell cycle, senescence, apoptosis, Wingless and Int-1 (Wnt), transforming growth factor beta (TGFβ), vascular endothelial growth factor (VEGF), Notch, Hippo, tumor necrosis factor alpha (TNFα), interleukin 1 beta (IL-1β), insulin like growth factor 1 (IGF-1), RUNX family transcription factor 2 (RUNX2), and endochondral ossification pathways. Cartilage homeostasis, macrophages and T cells activity and inflammatory mediators were identified by IPA as
targets of the miRNAs found in all the cell populations. Co-culture tests on macrophages and T cells confirmed the immuno-modulatory ability of CCs, ASCs, and BMSCs. The study findings support the rationale behind the use of cell-based therapy for the treatment of OA.

KEYWORDS
adipose stem cells, bone marrow stem cells, secretome, miRNAs, early osteoarthritis, immunomodulation, cartilage cells

Introduction

Cell therapy for the treatment of early osteoarthritis (OA) is essentially based on mesenchymal stromal cells (MSCs), mainly adipose tissue-derived (ASCs), and bone marrow-derived stem cells (BMSCs). These cell sources represent the elective choice because adipose tissue and bone marrow are easily harvestable and allow an adequate cell number (1) to be obtained.

The rationale for the use of these cells lies in the fact that they are able to respond to the environment in which they are placed, acting as protagonists of immunomodulation if they have to face antagonists or a hostile microenvironment (2).

Autologous chondrocytes also represent a therapeutic option for the treatment of joint conditions with specific reference to focal chondral lesions (3). However, apart from their regenerative potential, chondrocytes show immunomodulatory abilities (4), likely explaining their clinical effectiveness also in patients with early OA (5–9).

Donor matched cartilage cells (CCs), ASCs and BMSCs were previously compared, in a published paper of our research group, in term of their phenotype and secretory features (10). All the analyzed cell types shared a similar immunophenotype, negative for hematopoietic markers and positive for mesenchymal stromal cell markers, and were able to differentiate into the osteogenic and chondrogenic lineages. Moreover, an exhaustive multiplex-based analysis of the cell secretome revealed that CCs exhibited the largest amount of secreted growth factors overall, with a special presence of chondrogenic, angiogenic, and pro-mitogenic molecules (10).

Characterizing the ideal candidates for cartilage cell therapy in osteoarthritic patients is fundamental to face in the best way the degenerative processes leading to tissue loss, as well as to counteract the inflammatory infiltration that represents a severe issue in an arthritic joint (11). In this regard, immune cells, particularly macrophages (65% of the infiltrate) (12–14) followed by T cells (22% of the infiltrate) (14–17), are recruited from the bloodstream and infiltrate into the synovium, participating to the chronicization of the inflammatory and catabolic processes leading to early OA (18, 19). In particular, macrophages have a multifaceted role in OA and their phenotypic alterations were observed during the pathology development, with M1 (pro-inflammatory) macrophages elevated in synovium and M2 (anti-inflammatory/remodeling) macrophages decreased (20).

With respect to T cells, most of those found in the synovial membrane of patients with OA are helper T cells (CD4+), whereas cytotoxic T cells (CD8+) occur sparsely (21–23).

Using cell secretome and in particular extracellular vesicles (EVs) has been also indicated as a potential strategy to counteract OA (24). These vesicles carry proteins, nucleic acids and lipids playing important roles in the intercellular communication and representing useful biomarkers for physiopathological conditions (25). EV-embedded micro RNAs (miRNAs) are small non-coding RNAs playing important roles in post-transcriptional regulation of biological processes even in cartilage (26). The expression profile of miRNA molecules is exploitable as a tool to have picture of normal and pathological tissues, searching for biomarkers of disease and therapy also in the OA context (27).

Considering the clinical relevance of cell-based therapies in OA treatment, with the aim of identifying the best cell candidate, the objective of the present study is to predict by bioinformatics the activity of the EV-embedded miRNAs secreted by CCs, ASCs, and BMSCs, and involved in OA and verify the immunomodulatory potential of these cells to support our bioinformatics findings. The knowledge of the interaction of these cells and immune cells will help to optimize the autologous cell-based therapeutic strategies for OA management.

Materials and methods

Isolation and expansion of cartilage cells, adipose tissue-derived and bone marrow-derived stem cells

This study was approved by the local Institutional Review Board (M-SPER-015). After patients’ informed written consent, articular cartilage harvested from superficial areas of femoral head/neck, bone marrow from femoral channel and subcutaneous adipose tissue from hip fat deposit were
collected from 2 females (53 and 56 y/o) and 1 male (41 y/o) having OA (Kellgren–Lawrence III–IV), who underwent total hip replacement.

Cartilage cells and ASCs were isolated by enzymatic digestion, whereas BMSCs were selected for plastic adherence. All these cell types were characterized, as previously reported (10). Cells were seeded at a density of 5,000 cells/cm², detached after 7 days and expanded for 14 days (2 passages). At passage 2 cells were frozen in liquid nitrogen using heat-inactivated FBS added with 10% (v/v) DMSO at concentration of 3–5 × 10⁶ cells/vial. After thawing, cells were cultured for other 7 days until passage 3.

Cartilage cells were cultured in high glucose DMEM supplemented with 10% FBS, 200 mM glutamine L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, 10 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), 1 mM sodium pyruvate (all reagents from Thermo Fisher Scientific Waltham, MA, USA). ASCs and BMSCs were cultured in α-MEM supplemented as described above, adding 5 ng/mL fibroblast growth factor 2 (FGF-2) (PeproTech, Rocky Hill, NJ, USA), to preserve their stemness features and proliferative potential (28, 29). Cells were maintained at 37°C, 5% CO₂, and 95% humidity.

Isolation of extracellular vesicles

Cartilage cells, ASCs, and BMSCs at passage 3 and at 90% confluence were washed with phosphate buffered saline (PBS) and serum free medium was added for 48 h. The culture supernatants (30 mL) were collected and differentially centrifuged at 4°C with the following steps: 376 × g for 15 min, 1,000 × g for 15 min, 2,000 × g for 15 min, 4,000 × g for 15 min, 4,000 × g for 15 min. The cleared supernatants were ultra-centrifuged at 100,000 × g for 3 h at 4°C in a 70 Ti rotor (Beckman Coulter, Pasadena, CA, USA) to obtain EVs. EV pellets were suspended in 100 µL PBS, counted and characterized in term of size, shape, and surface marker expression, as previously reported (30–32). Cell viability after 48 h in serum free medium was checked with a NucleoCounter NC-3000 (ChemoMettec, Allerød, Denmark) to verify that culture in serum free medium did not compromise cell viability. CCs showed a viability of 95.1 ± 0.5%, BMSCs of 96.5 ± 2.0%, and ASCs of 97.2 ± 1.4%.

Expression of extracellular vesicles-embedded micro RNA

The EV pellets were dissolved by Trizol and low molecular weight nucleic acids (<200 nt) were obtained with miRNeasy Kit and RNeasy CleanUp Kit (Qiagen, Hilden, Germany). During the extraction, synthetic ath-miR-159a was added as a spike-in to each sample as quality control for the process.

Reverse transcription and pre-amplification were performed to obtain cDNAs to be used as template for Real-Time PCR with the QuantStudio 12 K Flex OpenArray® Platform (QS12KFlex). The Open Array covered 754 human miRNA sequences from the Sanger miRBase v21 Gene, divided into A and B panels.

micro RNA data normalization

The miRNA expression was analyzed by Expression Suite Software (Life Technologies, Carlsbad, CA, USA). The spike-in was used to equalize A and B panels of the Open Array and to balance any technical difference during the process (33). Ct of 27 was considered as a threshold for the presence/absence of amplification. Global mean, calculated from miRNAs amplified in all samples, was the normalization method (34). The relative quantification 2−ΔCt was used to determine the miRNA expression.

micro RNA target prediction analysis

The bioinformatics Mientournet tool (35) was used for validated target prediction analysis, considering miRTarBase database for experimentally validated miRNA-target interactions. The analysis specifically focused on miRNA embedded in the EVs from CCs, ASCs, or BMSCs.

Ingenuity Pathway Analysis (IPA; Ingenuity® Systems, Redwood City, CA, USA) was used to identify, among all the analyzed miRNAs, the ones experimentally observed as involved in OA. To achieve this, the miRNA Target Filter tool was applied as follows: “experimentally observed” and disease “skeletal and muscular disorders,” especially involved in “osteoarthritis pathway,” or “inflammatory response.” Relevant pathways for immune response and OA were identified by the IPA tool using the target genes of miRNA of the three cell populations.

Cell modulation of macrophages switch

Human peripheral blood mononuclear cells were isolated by Ficoll (GE Healthcare, Chicago, IL, USA) density gradient separation from 16 buffy coats of healthy donors obtained from the local blood bank. Monocytes were then isolated using CD14 magnetic microbeads (MACS, Miltenyi, Bergisch Gladbach, Germany).
Germany) (36). After isolation, monocytes were counted and frozen in liquid nitrogen using heat-inactivated FBS added with 10% (v/v) DMSO at concentration of 10 × 10^6 cells/vial.

After thawing, 90 × 10^6 pooled monocytes were seeded at a density of 2 × 10^5 cells/cm^2 in RPMI 1640 (Gibco, St. Louis, MO, USA) added with 10% heat-inactivated FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, 200 mM glutamine (Thermo Fisher Scientific, Waltham, MA, USA). The strategy to pool monocytes was used to achieve a suitable cell number for the following tests. To differentiate monocytes into M0 macrophages, 20 ng/mL of macrophage colony-stimulating factor (M-CSF, Peprotech Inc., Rocky Hill, NJ, USA) was added to the medium (37–39). The medium was refreshed every 2/3 days until day 9. In parallel, at day 2, CCs, ASCs, and BMSCs from the three matched donors were thawed and plated on polycarbonate membrane of trans-wells (Merck, Darmstadt, Germany) at a density of 0.7 × 10^5 cells/trans-well and left in appropriate expansion medium to favor cell adhesion. At day 7, trans-wells seeded with CCs, ASCs, or BMSC were transferred to the macrophage plates. During the co-culture phase, which lasted 2 days, macrophage culture medium and the appropriate expansion medium of CCs, ASCs, and BMSC were combined in a 1:1 ratio. Non-co-cultured M0 macrophages were used as control.

After 2 days of co-culture, the macrophage immunophenotype was analyzed by flow cytometry. Briefly, macrophages were washed with PBS, detached with non-enzymatic cell dissociation buffer (Thermo Fisher, Frankfurt, Germany) and centrifuged at 500 × g for 5 min to collect them. Macrophages were then suspended in MACS buffer (Miltenyi Biotec, Bergisch Gladbach, Germany), treated with FcR Blocking Reagent (Miltenyi Biotec, Bergisch Gladbach, Germany) for 10 min at 4°C to block unwanted binding of antibodies to human Fc receptor and counted. Afterward, 10^5 cells were stained to evaluate the expression of cell surface markers with the following antibodies: anti-human CD80-APC (Clone REA661, Miltenyi Biotec, Bergisch Gladbach, Germany) and CCR7-APC/Fire-750 (Clone G043H7, Biolegend, San Diego, CA, USA) for M1 phenotype, anti-human CD206-FITC (Clone 15–2, Biolegend, San Diego, CA, USA) for M2a phenotype, and anti-human CD163-PE (Clone GHI/61, Biolegend, San Diego, CA, USA) for M2c phenotype. Unstained cells were used as negative control. All the stains were performed at 4°C for 20 min in the dark. Data were acquired using a Cytoflex flow cytometer (Beckman Coulter, Brea, CA, USA) acquiring a minimum of 10,000 events.

Characterization of T cells after co-culture

After isolation by Ficoll, 2 × 10^5 human peripheral blood cells (PBMCs) were co-cultured with 1 × 10^5 or 2 × 10^5 CCs, ASCs, and BMSCs, plated 2 days before. After 4 days of co-culture, PBMCs were collected and stained with monoclonal anti-human CD3-APC antibody (Clone UCHT1, Biolegend, San Diego, CA, USA) for gating lymphocytes and with monoclonal anti-human CD4-PE/Cy7 antibody (Clone RPA-T4, Biolegend, San Diego, CA, USA), and monoclonal anti-human CD8-PerCP antibody (Clone SK1, Biolegend, San Diego, CA, USA) to evaluate the ability of cells to modify the CD4^+ /CD8^+ T cells ratio. Cells were analyzed on a Cytoflex flow cytometer acquiring 10,000 events.

Statistical analysis

To analyze the data obtained from tests on macrophages and T cells, the normality of data distribution was assessed by Kolmogorov–Smirnov test. Unpaired Student’s t-test was used to compare control cells and co-cultured cells. Significance difference was considered for p ≤ 0.05. Statistical analysis was performed using GraphPad software (GraphPad Prism v5.00, La Jolla, CA, USA).

Results

Cartilage cells, adipose tissue-derived and bone marrow-derived stem cells share the expression of most micro RNAs

Among all the 428 detected miRNAs, 325 were embedded in the EVs from all the 3 cell populations, 26 were embedded in the EVs from CCs and ASCs, 21 were embedded in the EVs from CCs and BMSCs, and 17 were embedded in the EVs from ASCs and BMSCs. The miRNAs selectively embedded in the EVs from only one cell population were 16 from CCs, 12 from ASCs, and 11 from BMSCs. The list of all the analyzed miRNAs and their C^2F in each single cell population is showed in Supplementary Table 1.

The lists of miRNAs embedded only in the EVs from each single cell population with target genes were retrieved by setting at least two gene-miRNA interactions (Supplementary Tables 2–4) as a threshold. Functional enrichment analysis was conducted by the open-source tools KEGG pathway, Reactome, and Wikipathway (Figures 1, 2). Significant pathways overrepresented within the targets of selected miRNAs are listed and indicated by circles, starting with those that are common to at least two miRNAs. Circles are colored according to the significance of the enrichment and their size is proportional to the number of involved targets. Bioinformatics analysis evidenced that no relevant pathways were modulated by miRNAs embedded only in the EVs from ASCs, whereas some relevant pathways were modulated by miRNAs embedded...
FIGURE 1
Functional enrichment analysis on micro RNAs (miRNAs) selectively expressed by cartilage cells (CCs). This analysis was conducted by KEGG pathway (A), Reactome (B), and WikiPathway (C). Significant pathways are listed and represented by circles colored according to the significance of the enrichment and their size is proportional to the number of target genes regulating the described signaling pathways.

in the EVs from CCs and BMSCs. In particular, for CCs miR-17-3p, miR-25-5p, miR-200c-3p, and miR-449a showed the highest number of interactions (Supplementary Table 2). These miRNAs putatively modulate cell cycle, senescence, apoptosis, Wingless and Int-1 (Wnt), transforming growth factor beta (TGFβ), vascular endothelial growth factor (VEGF), Notch, Hippo, tumor necrosis factor alpha (TNFα) and interleukin 1 beta (IL-1β) signaling (Figure 1), potentially related to OA.

Concerning BMSCs, the highest number of interactions was showed by miR-141-3p, miR-143-5p, miR-363-3p, miR-205-5p,
and miR-483-3p (Supplementary Table 4) mainly involved in apoptosis, TGFβ, insulin like growth factor 1 (IGF-1), RUNX family transcription factor 2 (RUNX2), and endochondral ossification pathways (Figure 2).

All the miRNAs embedded in the EVs from all the three populations of cells were analyzed by IPA tool to identify their involvement in OA and inflammation (Table 1). None of the miRNAs embedded only in the EVs from CCs was involved
TABLE 1 micro RNAs (miRNAs) in the extracellular vesicle (EVs) from cartilage cells (CCs), adipose tissue-derived (ASCs), and bone marrow-derived stem cells (BMSCs) and their target genes identified as involved in inflammation or osteoarthritis (OA) (target genes in blue) by ingenuity pathway analysis (IPA).

| miRNA   | Fc vs. ASCs | Fc vs. BMSCs | Target genes                                      |
|---------|-------------|--------------|---------------------------------------------------|
| miR-140-5p | 36.6        | 5.4          | ADAMTS5, HDAC4, IGFBP5, SMAD3, and VEGFA          |
| miR-302a-3p | 8.4         | 4.0          | DKK1, PRKACB, RELA, and VEGFA                    |
| miR-101-3p | 4.0         | 3.7          | PTGS2                                            |
| miR-138-5p | 3.5         | 3.2          | ROCK2                                            |
| miR-24-3p | 2.1         | 2.0          | ACVR1B, MAP2K4, MAPK14, NOTCH1, SMAD3, SMAD4, and SMAD5 |
| miR-126-3p | 2.0         | 2.5          | IRS1, PIK3R2, and VEGFA                         |
| miR-210  | 10.8        | 1.7          | ACVR1B                                           |
| miR-532-5p | 9.8         | 1.0          | RUNX3                                            |
| miR-196b-5p | 8.9         | 0.7          | S100A9                                           |
| miR-353-5p | 7.8         | 1.0          | PTPN11, PXN, RASA1, and SRF                       |
| miR-203  | 6.9         | 1.7          | CREB1, PRKCA, RUNX2, SOCS3, and SRC               |
| miR-21-5p | 4.5         | 1.7          | ACTA2, BMPR2, JAG1, PIK3R1, SOCS5, TGFB1, TIMP3, and TNF |
| miR-100-5p | 4.3         | 1.0          | FGF3, IGF1, and MTOR                            |
| miR-615-5p | 3.1         | 1.3          | IGFR1                                            |
| miR-185-5p | 2.6         | 1.0          | AKT1, CDC42                                      |
| miR-186-5p | 2.3         | 1.0          | FOXO1                                            |
| miR-130a-3p | 2.0        | 1.0          | SMAD4                                            |
| miR-1285-3p | 0.6        | 8.2          | AKT2                                             |
| miR-487b | 1.4         | 3.2          | MAP2K4                                           |
| miR-155-5p | 1.9         | 2.3          | CCN1, CEBPB, CTNNB1, FADD, MYD88, PRKCI, SMAD1, SMAD2, SOCS1, and TCF7L2 |
| miR-191-5p | 1.9         | 1.4          | IL6                                              |
| miR-31-5p | 1.3         | 1.6          | Casr, HIF1A                                      |
| miR-214-3p | 1.0         | 1.0          | ATF4                                             |
| miR-34a-5p | 0.9         | 0.6          | BCL2, CREB1, HDAC1, JAG1, MAP2K1, NOTCH1, SIRT1, and VEGFA |
| miR-29a-3p | 1.6         | 1.3          | ACVR2a, CDC42, HDAC4, PIK3R1, SP1, TGFB3, TGFB1, and TGFB2 |
| miR-26a-5p | 1.5         | 1.4          | PTGS2, SMAD1, and TGFB2                          |
| miR-27a-3p | 1.8         | 1.4          | FADD, FOXO1, GRB2, IGF1, MEF2C, MMP13, NOTCH1, PDPK1, PPARG, PXN, SMAD3, SMAD4, and SMAD5 |
| miR-487b | 1.4         | 3.2          | MAP2K4                                           |
| miR-155-5p | 1.9         | 2.3          | CCN1, CEBPB, CTNNB1, FADD, MYD88, PRKCI, SMAD1, SMAD2, SOCS1, and TCF7L2 |
| miR-191-5p | 1.9         | 1.4          | IL6                                              |
| miR-31-5p | 1.3         | 1.6          | Casr, HIF1A                                      |
| miR-214-3p | 1.0         | 1.0          | ATF4                                             |
| miR-34a-5p | 0.9         | 0.6          | BCL2, CREB1, HDAC1, JAG1, MAP2K1, NOTCH1, SIRT1, and VEGFA |
| miR-29a-3p | 1.6         | 1.3          | ACVR2a, CDC42, HDAC4, PIK3R1, SP1, TGFB3, TGFB1, and TGFB2 |
| miR-26a-5p | 1.5         | 1.4          | PTGS2, SMAD1, and TGFB2                          |
| miR-27a-3p | 1.8         | 1.4          | FADD, FOXO1, GRB2, IGF1, MEF2C, MMP13, NOTCH1, PDPK1, PPARG, PXN, SMAD3, SMAD4, and SMAD5 |
| miR-132-3p | 0.8         | 0.7          | MMP9                                             |
| miR-22-3p | 1.6         | 1.1          | BMP7, SRF                                        |
| miR-25-3p | 1.7         | 1.2          | BMPR2, ITG5A, ITG8, and MAP2K4                   |
| miR-23a-3p | 1.8         | 1.2          | HES1, NOTCH1, SMAD3, SMAD4, and SMAD5            |
| miR-19a-3p | 1.1         | 0.8          | BMPR2, CCN2                                       |
| miR-125a-5p | 0.6        | 0.6          | BMPFR1, CASP6, CASP7, ELAVL1, IGFBP3, IL1RN, MYD88, and SMO |
| miR-128 | 1.7         | 1.0          | TGFB1                                            |
| miR-491-5p | 1.6         | 1.4          | BCL2L1                                           |
| miR-222-5p | 0.8         | 0.7          | ACTA2, ROCK2                                      |
| miR-18a-5p | 1.2         | 0.6          | CCN2, HIF1A                                      |
| miR-199a-5p | 0.9        | 0.7          | HIF1A, SIRT1                                     |
| miR-15a-5p | 1.7         | 0.9          | BCL2, FGFR1, GFR1, GRB10, GRB2, JFNG, IGF1, IGF1R, ITGAI, JUN, MAP2K1, MAP2K4, MAPK3, PAX1, PTGS2, RAF1, VEGFA, and WNT3A |
| miR-1271-5p | 1.4        | 1.8          | FOXO1, IRS1                                      |
| miR-335-3p | 1.5         | 0.8          | TGFB1, TGFB2                                     |
| miR-139-5p | 1.3         | 0.8          | FOXO1, IGF1R, and SHC1                           |
| miR-150-5p | 1.0         | 1.0          | AKT, CEBPB, and VEGFA                            |
| miR-184 | 1.2         | 1.2          | AKT2                                             |
| miR-223-3p | 0.8         | 0.7          | IRS1, MEF2C                                      |

(Continued)
### TABLE 1 (Continued)

| miRNA     | Fc vs. ASCs | Fc vs. BMSCs | Target genes |
|-----------|-------------|--------------|--------------|
| miR-296-3p| 0.8         | 1.3          | CREB1        |
| miR-193a-3p| 0.8         | 0.9          | PTK2, RPS6KB2|
| miR-221-3p| 0.4         | 0.3          | DDT1, FOS, FOXO3, MMP1, PIK3R1, and TIMP3 |
| miR-149-5p| 0.3         | 0.5          | RAP1A, RAP1B |
| miR-218-5p| 0.1         | 0.1          | PIK3C2A, PLCG1, RUNX2, and SP1 |
| miR-143-3p| 0.5         | 0.1          | BCL2, IGFBP5, KRAS, and MAPK12 |
| miR-181a-5p| 0.2        | 0.1          | BCL2, KRAS, TIMP3 |
| miR-197-3p| 0.4         | 0.5          | ACVR1        |
| miR-296-5p| 0.5         | 0.3          | BCL2         |
| miR-503   | 0.1         | 0.4          | FGF2, FGF1   |
| miR-542-3p| 0.4         | 0.5          | PTGS2        |
| miR-145-5p| 0.4         | 0.1          | IGF1R, IR51, MMP1, RASA1, and SOX9 |
| miR-124-3p| 0.02        | 0.9          | CCN2, GLI3, HDAC4, HES1, ITGB1, JAG1, MAPK14, PGR, RELA, SMAD5, SOX9, SP1, and STAT3 |
| miR-204-5p| 0.2         | 0.6          | ITGB4, MMP3, MMP9, SHC1, and TGFBR2 |
| miR-146a-5p| 0.3        | 0.6          | CHUK, CXCL8, FADD, IFNA1/IFNA13, IFNB1, IL10, IL1F10, IL1R1, IL1RAP, IL1RAPL2, IL1R1, IL6A, IL6B, IL6G, IL6RN, IL17, NOS2, TLR4, and TRAF6 |
| miR-422a  | 0.4         | 0.6          | CASP9, IGF1R, and PDPK1 |
| miR-34b-5p| 0.5         | 0.7          | CREB1, VEGFA |
| miR-142-3p| 0.6         | 0.3          | BCL2L1, PRKCA |
| miR-7-5p  | 1.1         | 0.3          | FO5, IRS1, IRS2, p70 S6k, and RAF1 |
| miR-106a-5p| 0.7        | 0.5          | BCL2, BMPR2, CREB1, CXCL8, JAK1, MMP3, PPARG, STAT3, TGFBR2, TNF, and VEGFA |
| miR-193a-5p| 0.6        | 0.5          | IL10, MTO1, and PIK3R3 |
| miR-324-5p| 1.2         | 0.5          | GLI1, SMO, and SRF |
| miR-30a-3p| 1.1         | 0.5          | CCN1, PIK3C2A |
| let-7a-5p | 2.6         | 0.5          | BCL2L1, CASP3, ITGB3, KRAS, NEDD4, NRS4, PTGS2, RAS, TGFBR1, TGFBR2, and TLR4 |
| miR-9-5p  | 0.2         | 2.3          | FOXO1, JAK1, JAK2, and NFKB1 |
| miR-133a  | 2.3         | /            | CCN2, IGF1R, RUNX2, and SRF |
| miR-486-5p| 1.1         | /            | FO5O1        |
| miR-122-5p| 1.7         | /            | AKT3 MAPK11  |
| miR-200b-3p| 0.8        | /            | PLCG1        |
| miR-135b-5p| /          | 0.9          | JAK2, RUNX2, and SMAD5 |

In bold fold change Fc ≥ 2 or ≤0.5 of expression in CCs in comparison with ASCs and BMSCs considered of interest.

In OA. Six miRNAs (miR-140-5p, 302a-3p, 101-3p, 138-5p, 24-3p, and 126-3p) appeared up-regulated in CCs in comparison with both ASCs and BMSCs. Additional 13 miRNAs (miR-210, miR-332-5p, miR-196b-5p, miR-335-5p, miR-203, miR-21-5p, miR-100-5p, miR-615-5p, miR-185-5p, miR-186-5p, miR-130a-3p, let-7a-5p, and miR-133a) were up-regulated in the EVs from CCs in comparison with ASCs, whereas only 4 miRNAs (miR-1285-3p, miR-487b, miR-155-5p, and miR-9-5p) were up-regulated in the EVs from CCs in comparison with BMSCs.

Ten miRNAs (miR-221-5p, miR-149-5p, miR-218-5p, miR-143-5p, miR-181a-5p, miR-197-3p, miR-296-5p, miR-503, miR-542-3p, and miR-145-5p) were down-regulated in the EVs from CCs in comparison with both ASCs and BMSCs. Additional six miRNAs (miR-124-3p, miR-204-5p, miR-146a-5p, miR-422a,
miR-34b-5p, and miR-9-5p) were down-regulated in the EVs from CCs in comparison with ASCs, whereas seven miRNAs (miR-142-3p, miR-7-5p, miR-106a-5p, miR-193a-5p, miR-324-5p, miR-30a-3p, and let-7a-5p) were down-regulated in the EVs from CCs in comparison with BMSCs.

Finally, four miRNAs (miR-125b-1-3p, miR-129-5p, miR-18a-3p, and miR-375) in the EVs from ASCs and BMSCs, three in the EVs from ASCs (miR-141-3p, miR-205-5p, and miR-483-3p), and one in the EVs from BMSCs (miR-219-5p) were involved in OA and not expressed in the EVs from CCs.

Micro RNAs in the EVs from CCs, ASCs, and BMSCs and their target genes identified as involved in inflammation or OA by IPA are reported in Table 1. Starting from target genes retrieved, relevant pathways for immune response and OA were identified by IPA and reported in Figure 3. Briefly, macrophages and T cells as actors and pro- and anti-inflammatory cytokines and mediators were identified as modulated by target genes of miRNAs of interest for what concerns immune response and signaling. Finally, cartilage homeostasis and cell proliferation-related pathways involved in OA modulated by the identified target genes were observed.

### Discussion

The main findings of the present investigation show that there was a similar basal expression of EV-embedded miRNAs in the CCs and both types of MSCs. In general, cartilage homeostasis-related pathways are identified as targets of the miRNAs found in all the cell populations. Interestingly, macrophages and T cells are actors potentially modulated by

**Cartilage cells, adipose tissue-derived and bone marrow-derived stem cells modulation of T cell survival and phenotypes**

The co-culture of all the three cell types and PBMCs showed a decrease in the CD3+ T lymphocytes survival (Figure 5A, $p < 0.01$ for CCs and ASCs and $p < 0.05$ for BMSCs). When looking at T cell phenotype, a decrease in CD4+ T cells survival was observed in CCs and ASCs ($p < 0.05$) (Figure 5B). On the contrary, CD8+ T cells percentage increased in presence of CCs and ASCs ($p < 0.01$) (Figure 5C).
miRNAs in the EVs from all the three cell types. Donor-matched CCs and MSCs behave similarly in the modulation of the anti-inflammatory macrophages polarization and of the T cell survival and phenotypes. Each cell population presents specific properties to be exploited to treat early OA. Of the 3 cell populations, ASCs seem to be the most anti-inflammatory, but the least pro-remodeling ones, whereas CCs and BMSCs show a more prominent ability of inflammatory modulation and remodeling, toward the restoration of tissue homeostasis. This aspect is reasonable also considering the affinity of the CCs with the cartilage and of the BMSCs with the subchondral bone. On the other side, ASCs would be more useful to counteract the immune cells when placed in an inflammatory microenvironment. Finally, because these cells showed immunomodulatory ability, their potential use to facilitate the resolution of OA induced inflammation and cartilage regeneration should be advised.

Our data are in line with those reported by previous publications. In co-culture with non-polarized macrophages, CCs have already shown an enhancement in maturation (19, 40–43). Furthermore, CCs were able to shift the M1 macrophage phenotype toward the M2-like phenotype (43) and to modulate pro-inflammatory macrophage activity by reducing MHC-II expression and TNF-α secretion (44). The anti-inflammatory and pro-regenerative interaction of CCs and macrophages is particularly clinically relevant for the achievement of the joint homeostasis in a patient who undergoes cell therapy in an OA context.

In this study, we also observed the MSC ability to modulate macrophage polarization. Other scientific reports analyzed the ability of ASCs in co-culture with synovial cells to interact with macrophages, showing that the amount of synovial macrophages differently induced or down-modulated inflammatory and degradative factors (45). BMSCs previously showed immunomodulatory ability in co-culture with macrophages. These cells promoted an anti-inflammatory phenotype of macrophages, assessed in term of decrease in M1-cytokines (TNFα and IL-1β) (46, 47) and increase of
Modulation of T cell survival and phenotype by cartilage cells (CCs), adipose tissue-derived (ASCs), and bone marrow-derived stem cells (BMSCs). For CD3⁺ (A), CD4⁺ (B), and CD8⁺ (C) cell representative density plots show T cells co-cultured with CCs. Floating bars represent mean to max percentages and mean values of cells positive for the different analyzed markers in T cells and co-cultured T cells with CCs, ASCs, and BMSCs. N = 3; ∗p < 0.05, ∗∗p < 0.001.

These results are interesting since lymphoid cell aggregates, containing primarily CD3⁺ T lymphocytes, were found in the synovial membrane of the 65% of patients with OA (52) and the most prevalent T cells type found in the synovium were T helper cells (CD3⁺, CD4⁺, and CD8⁻) (23, 53), acknowledged as having a pivotal role in the pathogenesis of OA (54). Cytotoxic/suppressor T cells occur sparsely and are not the predominant T cell type in the synovial aggregates of OA patients (21). Nevertheless, these cells likely shape the pathogenesis of OA, although they do not play the most important role in this disease (55). Considering these observations, the lack of promotion of CD4⁺ and the slight promotion of the CD8⁺ T cell survival mediated by CCs and

M2-cytokines (CCL17, CCL22) secretion (47) or of increase in the frequency of M2-macrophages (48).

With respect to T cells, CCs already showed a reduced induction of proliferation and activation in allogeneic T cells and a potent ability to suppress allogeneic T cell proliferation, which was dependent on nitric oxide production (44).

In our study, CD4⁺ helper T cells did not proliferate, whereas CD8⁺ cytotoxic T cells showed higher survival when co-cultured with CCs and ASCs. A possible reason for this response could be the differential expression on CCs and ASCs of MHC class II and I, presenting to helper and cytotoxic T cells, respectively. In fact, these cells showed the expression of MHC class I, but not of MHC class II (49–51).
ASCs reflects a non-immunogenicity of these cells. This is particularly interesting for CD4+ cells, which are considered predominant and active in OA infiltrates, whereas the data reported for CD8+ cells should be better evaluated when their role in OA pathophysiology will be better elucidated.

The main limitation of the present study resides in the fact that, as with all the co-culture in vitro tests, these present the intrinsic limitation of being based on pre-established models. These models are unable to faithfully represent the dynamic OA pathophysiology. Nevertheless, if compared with in vitro models exploiting the conditioned medium to mimic the inflammatory status, the use of co-culture tests with more cell types allows at least in part overcoming this limitation. In fact, co-culture tests add complexity and dynamicity to classical in vitro tests, allowing for exploration of crosstalk between cells sharing the same environment. Another limitation is the number of donors used in this study. The results need to be confirmed in a wider population, but are useful to restrict the biological fields of investigation in the OA context.

Conclusion

In conclusion, this study is a proof-of-concept to support the idea that bioinformatics data need to be validated by means of co-culture tests, establishing in reality which pathways are activated by cell crosstalk and how much these pathways contribute in the overall outcome in the context of a biological process. In fact, although data derived by gene, miRNA and protein arrays are a precious mine of information, they can only provide an idea of the processes modulated by the cells. But, when these cells are placed in specific contexts, being competent, they respond to the stimuli they find in the environment, in turn producing mediators that stimulate both the cells themselves and those with which they interact. As a consequence, co-culture tests represent an essential step in the investigation of the effect of cell therapy in the modulation of a biological process, while the analysis of the expression of genes, miRNAs and proteins should be the tool that allows defining a modulation in a pro- or anti-inflammatory sense. Using this approach, we found that CCs, ASCs, and BMSCs are able to modulate macrophage phenotype and T cell survival, by promoting a general anti-inflammatory environment without inducing an inflammatory response mediated by immune cells, which usually infiltrate the synovial membrane of OA patients.

Author contributions

AC: conception and design, collection and/or assembly of data, data analysis and interpretation, and manuscript writing. FL, ER, PD, and FS: collection and/or assembly of data and final approval of the manuscript. SL: collection and/or assembly of data, data analysis and interpretation, and final approval of the manuscript. LZ: provision of the study material or patients and final approval of the manuscript. MM and LG: financial support and final approval of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work reported in this publication was funded by the Italian Ministry of Health, RCR-2021-23671217 project, under the Italian Musculoskeletal Apparatus Network RAMS.

Acknowledgments

We are grateful to Giovanna Chiorino for the support in the bioinformatics analysis of the data and Joshua Harliono for language editing.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Data availability statement

The data presented in this study are deposited in the OSF repository, accession number: https://osf.io/y96rc/?view_only=e96a9ba950cc469bb7cfeaa1162aas672.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.992386/full#supplementary-material
Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis.  
DOI: 10.1186/ar4545

membrane, synovial fluid and peripheral blood.

et al. CD4+CD25+/highCD127low/- regulatory T cells are enriched in rheumatoid

patterns of mononuclear cell infiltration and cytokine release in the affected joints.

6. Ferruzzi A, Buda R, Cavallo M, Timoncini A, Natali S, Giannini S. Cartilage repair procedures associated with high tibial osteotomy in varus knees: clinical results at 11years’ follow-up. Knee. (2014) 24:455–460. DOI: 10.1016/j.knee.2013.11.013

7. Kreuz PC, Muller S, Osendorf C, Kaps C, Erggelet C. Treatment of focal degenerative cartilage defects with polymer-based autologous chondrocyte grafts. arth. rheum. 2014.10.017

8. Minas T, Gomoll AH, Solhpour S, Rosenberger R, Probst C, Bryant T. Autologous chondrocyte implantation for joint preservation in patients with early osteoarthritis. Clin. Orthop. (2010) 468:147–57.

9. Sato M, Yamato M, Mitani G, Takagaki T, Hamashiki K, Nakamura Y, et al. Combined surgery and chondrocyte cell-sheet transplantation improves clinical and structural outcomes in knee osteoarthritis. NPJ Regen Med. (2019) 4:4. DOI: 10.1038/s41541-019-0059-5

10. De Luca P, Kouroupis D, Viganò M, Perucca Orfici C, Kaplan I, Zagra L, et al. Human diseased articular cartilage contains a mesenchymal stem cell-like population of chondrogen progenitors with strong immunomodulatory responses. J Clin Med. (2019) 8:243. DOI: 10.3390/jcm8040243

11. de Lange-Brokaar BJE, Ioan-Facsinay A, van Osch GJVM, Zuurmond AM, friends. J Cell Biol. (2013) 200:371–83.

12. Xie Y, Chen W, Zhao M, Xu Y, Yu H, Qin J, et al. Exploration of exosomal miRNAs from serum and synovial fluid in arthritis patients. Diagnostics. (2022) 12:239. DOI: 10.3390/diagnostics12020239

13. Liu Y, Wagner DR. Effect of expansion media containing fibroblast growth factor-2 and dexamethasone on the chondrogenic potential of human adipose-derived stromal cells. Cell Biol Int. (2012) 36:611–5. DOI: 10.1042/CL20110503

14. Solchaga LA, Penick K, Porter JD, Goldberg VM, Caplan AL, Welter JF. FGF-2 enhances the mitotic and chondrogenic potentials of human adult bone marrow-derived mesenchymal stem cells. J Cell Physiol. (2005) 203:398–409. DOI: 10.1002/jcp.20238

15. Ragni E, Colombari A, De Luca P, Libonati F, Viganò M, Perucca Orfici C, et al. miR-103a-3p and miR-22-5p are reliable reference genes in extracellular vesicles from cartilage, adipose tissue, and bone marrow cells. Front Bioeng Biotechnol. (2021) 9:632440. DOI: 10.3389/fbioe.2021.632440

16. Colombari A, Ragni E, Mortati L, Libonati F, Perucca Orfici C, Viganò M, et al. Adipose-derived mesenchymal stromal cells treated with interleukin 1 beta produced chondro-protective vesicles able to fast penetrate in cartilage. Cells. (2021) 10:1180. DOI: 10.3390/cells10051180

17. Mortati L, de Girolamo L, Perucca Orfici C, Viganò M, Brayda-Bruno M, Ragni E, et al. In vitro study of extracellular vesicles migration in cartilage-derived osteoarthritis samples using real-time quantitative multimodal nonlinear optics imaging. Pharmaceutics. (2020) 12:734. DOI: 10.3390/pharmaceutics12080734

18. Ragni E, Perucca Orfici C, De Luca P, Lugano G, Viganò M, Colombari A, et al. Interaction with hyaluronan matrix and miRNA cargo as contributors for in vitro potential of mesenchymal stem cell-derived extracellular vesicles in a model of human osteoarthritic synoviocytes. Stem Cell Res Ther. (2019) 10:109. DOI: 10.1186/s13287-019-1215-7

19. Dhaene B, Meftedigh P, Hellemons J, Vandesompele J. miRNA expression profiling: from reference genes to global mean normalization. In: Fan JB editor. Next-generation MicroRNA expression profiling technology. Totowa, NJ: Humana Press (2012). p. 261–72.

20. Licursi V, Conte F, Fiscon G, Paci P. MiENUT: an interactive web tool for microRNA target enrichment and network-based analysis. BMC Bioinform. (2019) 20:545. DOI: 10.1186/s12859-019-2105-x

21. Lopa S, Leis MJ, Moretti M, Lubbets E, van Oss GJVM, Bastiaensen-Jenniskens YM. Arthritis and non-arthritic synovial fluids modulate IL10 and IL1RA gene expression in differentially activated primary human monocytes. Osteoarthritis Cartilage. (2015) 23:1853–7. DOI: 10.1016/j.joca.2015.06.003

22. Spiller KL, Wrona EA, Romero-Torres S, Pallotta I, Graney PL, Wither CE, et al. Differential gene expression in human, murine, and cell line-derived macrophages upon polarization. Exp Cell Res. (2016) 347:1–13. DOI: 10.1016/j.yexcr.2015.10.007

23. Graney PL, Ben-Shaul S, Landau S, Bajpai A, Singh B, Eager J, et al. Macrophages of diverse phenotypes drive vascularization of engineered tissues. Sci Adv. (2020) 6.eaay6391.
39. Spiller KL, Anfang RR, Spiller KJ, Ng J, Nakazawa KR, Daulton JW, et al. The role of macrophage phenotype in vascularization of tissue engineering scaffolds. *Biomaterials*. (2014) 35:4477–88.

40. Fujihara Y, Takato T, Hoshi K. Immunological response to tissue-engineered cartilage derived from auricular chondrocytes and a PLLA scaffold in transgenic mice. *Biomaterials*. (2010) 31:1227–34. doi: 10.1016/j.biomaterials.2009.10.053.

41. Fujihara Y, Hikita A, Takato T, Hoshi K. Roles of macrophage migration inhibitory factor in cartilage tissue engineering. *J Cell Physiol*. (2018) 233:1490–9. doi: 10.1002/jcp.26036.

42. Fujihara Y, Abe T, Hoshi K. Controlling the phenotype of macrophages promotes maturation of tissue-engineered cartilage. *Tissue Eng Part A*. (2020) 26:1005–13.

43. Miyamoto Y, Kuhota K, Asawa Y, Hoshi K, Hikita A. M1-like macrophage contributes to chondrogenesis in vitro. *Sci Rep*. (2021) 11:21307.

44. Lohan P, Treacy O, Lynch K, Barry F, Murphy M, Griffin MD, et al. Culture expanded primary chondrocytes have potent immunomodulatory properties and do not induce an allogeneic immune response. *Osteoarthritis Cartilage*. (2016) 24:521–33. doi: 10.1016/j.joca.2015.10.005.

45. Manferdini C, Paolella F, Gabusi E, Silvestri Y, Gambari L, Cattini L, et al. From osteoarthritic synovium to synovial-derived cells characterization: synovial macrophages are key effector cells. *Arthritis Res Ther*. (2016) 18:83. doi: 10.1186/s13075-016-0983-4.

46. Gray A, Marrero-Berrios I, Weinberg J, Manchikalapati D, SchianodiCola J, Schloss RS, et al. The effect of local anesthetic on pro-inflammatory macrophage modulation by mesenchymal stromal cells. *Int Immunopharmacol*. (2016) 33:48–54. doi: 10.1016/j.intimp.2016.01.019.

47. Romero-López M, Li Z, Rhue C, Maruyama M, Pajarinen J, O’Donnell B, et al. Macrophage effects on mesenchymal stem cell osteogenesis in a three-dimensional In Vitro bone model. *Tissue Eng Part A*. (2020) 26:1099–111. doi: 10.1089/ten.TEA.2020.0041.

48. Gómez-Aristizábal A, Kim KP, Viswanathan SA. Systematic study of the effect of different molecular weights of hyaluronic acid on mesenchymal stromal cell-mediated immunomodulation. *PLoS One*. (2016) 11:e0147868. doi: 10.1371/journal.pone.0147868.

49. Samadi P, Saki S, Manouchihi H, Sherykhihasan M. Therapeutic applications of mesenchymal stem cells: a comprehensive review. *Curr Stem Cell Res Ther*. (2021) 16:323–53.

50. Russell KA, Chow NHC, Dukoff D, Gibson TWG, LaMarre I, Betts DH, et al. Characterization and immunomodulatory effects of canine adipose tissue- and bone marrow-derived mesenchymal stromal cells. *PLoS One*. (2016) 11:e0167442. doi: 10.1371/journal.pone.0167442.

51. Kondo M, Kameishi S, Kim K, Metzler NF, Maak TG, Hutchinson DT, et al. Safety and efficacy of human juvenile chondrocyte-derived cell sheets for osteochondral defect treatment. *NPJ Regen Med*. (2021) 6:65. doi: 10.1038/s41536-021-00173-9.

52. Saikas LJ, Scanzello C, Johanson N, Burkholder J, Mitra A, Salgame P, et al. T cells and T-Cell cytokine transcripts in the synovial membrane in patients with osteoarthritis. *Clin Diagn Lab Immunol*. (1998) 5:430–7. doi: 10.1128/CDLI.5.4.430-437.1998.

53. Symons JA, McCulloch JE, Wood NC, Duff GW. Soluble CD4 in patients with rheumatoid arthritis and osteoarthritis. *Clin Immunol Immunopathol*. (1991) 60:72–82. doi: 10.1016/0090-1229(91)90113-o.

54. Li Y-S, Luo W, Zhu S-A, Lei G-H. T cells in osteoarthritis: alterations and beyond. *Front Immunol*. (2017) 8:356. doi: 10.3389/fimmu.2017.00356.

55. Hsieh JL, Shiau AL, Lee CH, Yang SL, Lee BO, Jou IM, et al. CD8+ T cell-induced expression of tissue inhibitor of metalloproteases-1 exacerbated osteoarthritis. *Int J Mol Sci*. (2013) 14:19951–70. doi: 10.3390/ijms141019951.